Consensus $110.67M. The company said, “During the audit of Medicx Health, it was determined that certain revenue streams for messages executed through Medicx Health’s channel partners, historically recognized on a gross basis, will now be recognized on a net basis. Consequently, the Company is updating its revenue guidance for this change and now anticipates revenue to be at least $100 million for 2024 as a result of this gross-to-net accounting treatment. Importantly, the Company’s adjusted EBITDA guidance remains unchanged, at greater than $11 million for 2024.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on OPRX:
- OptimizeRx Provides an Update on the Timing of Earnings Call and Reaffirms Prior Revenue and Adjusted EBITDA Estimates for FY2023
- OptimizeRx Powers Walmart’s ‘Specialty Pharmacies of the Community’ Outreach Effort
- OPRX Upcoming Earnings Report: What to Expect?
- OptimizeRx to Participate in Upcoming Investor Conferences
- OptimizeRx Announces Board Changes in Press Release
